BHVN
Biohaven·NYSE
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 0
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About BHVN
Biohaven Ltd.
A commercial-stage biopharmaceutical company with a portfolio of innovative, best-in-class therapies to debilitating neurological and neuropsychiatric diseases
215 Church Street, New Haven, Connecticut 06510
--
Biohaven Ltd., is a British Virgin Islands commercial limited liability company incorporated in the British Virgin Islands on May 2, 2022. The company is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience and oncology. The company is advancing a portfolio of innovative therapies, leveraging proven drug development experience and multiple proprietary drug development platforms.
Company Financials
EPS
BHVN has released its 2025 Q3 earnings. EPS was reported at -1.64, versus the expected -1.61, missing expectations. The chart below visualizes how BHVN has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
